

Supplementary Table 1. Clinical characteristics of 10 patients with COVID-19-associated pulmonary aspergillosis

Age, yr/Sex	Comorbidities	Severity	APACHE	Baseline Cr	Baseline lymphocyte	Oxygen therapy	Corticosteroid (mean daily dose), mg	Days to CAPA from admission	Consensus criteria	Clinical features	Mycologic evidence (OD)	Fungus culture	Antifungal treatment (dose)	Days to treatment from diagnosis	Duration of anti-fungal agents	Outcome
72/F	DM	Critical	21	2.06	860.1	MV	125	7	Probable	Increased patchy consolidation with GGO	GM (>3.5)	<i>A. fumigatus</i> on TA	LAB (3 mg/kg)	0	3	Death
78/F	CLD (CHC)	Critical	11	1.04	696.0	MV	99	12	Probable	Increased pulmonary infiltration	GM (2.82)	No growth	None	NA	0	Death
27/F	HM, post-HSCT	Critical	7	0.93	951.7	HFNC	405.7	11	Probable	Increased patchy consolidation with GGO	GM (0.64)	No growth	Voriconazole (200 mg bid)	9	40	Alive
87/M	CKD, COPD, HF, SC	Critical	13	2.89	122.0	MV	189.5	9	Probable	Increased patchy consolidation with GGO	GM (3.20)	No growth	None	NA	0	Death
63/M	CKD, CLD, DM	Critical	28	3.92	686.7	MV	168.0	1	Probable	Multifocal consolidation with GGO	GM (2.42)	No growth	LAB (3 mg/kg)	1	14	Death
77/M	DM	Critical	16	0.98	524.1	HFNC	103.8	9	Probable	A thin-walled cavitary nodule in LUL	GM (4.30)	<i>A. niger</i> on sputum	Voriconazole (200 mg bid)	5	38	Alive
64/M	DM	Severe	14	0.87	290.3	NP	113.5	17	Probable	Bilateral opacities with consolidation	GM (1.46)	No growth	Itraconazole (200 mg bid)	2	NA ^a	Alive
75/F	COPD	Critical	11	0.56	2,595.2	HFNC	34.3	0	Probable	Increased patchy consolidation with faint GGO	GM (1.64)	No growth	Voriconazole (200 mg bid)	2	38	Alive
71/M	DM	Critical	20	0.61	879.1	MV	85.1	10	Probable	Increased pulmonary opacities	GM (0.99)	<i>A. fumigatus</i> on TA	Voriconazole (200 mg bid)	2	NA ^a	Alive
71/F	HM	Critical	5	0.48	259.2	MV	163.8	35	Probable	Bilateral consolidation with GGO	GM (1.05)	NA	Voriconazole (200 mg bid)	1	13	Death

Corticosteroid doses are presented as methylprednisolone.

COVID-19, coronavirus disease 2019; APACHE, acute physiology and chronic health evaluation; Cr, creatinine; CAPA, COVID-19-associated pulmonary aspergillosis; OD, optical density; DM, diabetes; MV, mechanical ventilation; GGO, ground-glass opacity; GM, galactomannan; TA, tracheal aspirate; LAB, liposomal amphotericin B; CLD, chronic liver disease; CHC, chronic hepatitis C; NA, not available; HM, hematologic malignancy; HSCT, hematopoietic stem cell transplantation; HFNC, high-flow nasal cannula; bid, twice daily; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; HF, heart failure; SC, solid cancer; NP, nasal prong.

^aIt was impossible to trace due to transfer to hospital for recovery after medical condition has improved.